5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma

Journal of Immunology

Volumn 186, Issue 1, 2011, Pages 576-583

  Yao, Xianglan ^a   Dai, Cuilian ^a   Fredriksson, Karin ^a   Dagur, Pradeep K ^a   McCoy, J Philip ^a   Qu, Xuan ^a   Yu, Zu Xi ^a   Keeran, Karen J ^a   Zywicke, Gayle J ^a   Amar, Marcelo J A ^a   Remaley, Alan T ^a   Levine, Stewart J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; COLLAGEN TYPE 3; EOTAXIN; EOTAXIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; PROTEIN 5A; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CONTROLLED STUDY; DERMATOPHAGOIDES; EOSINOPHIL; FEMALE; GOBLET CELL; HISTOPATHOLOGY; HYPERPLASIA; LUNG LAVAGE; LYMPHOCYTE; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH17 CELL; TH2 CELL;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-ASTHMATIC AGENTS; APOLIPOPROTEIN A-I; ASTHMA; BRONCHIAL HYPERREACTIVITY; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MACROPHAGE ACTIVATION; MICE; MICE, INBRED A; MOLECULAR MIMICRY; PEPTIDE FRAGMENTS; PYROGLYPHIDAE;

EID: 79251554687     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001534     Document Type: Article

References (69)

1. Navab, M., G. M. Anantharamaiah, S. T. Reddy, and A. M. Fogelman. 2006. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat. Clin. Pract. Cardiovasc. Med. 3: 540-547.
2. Plump, A. S., C. J. Scott, and J. L. Breslow. 1994. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA 91: 9607-9611.
3. Sethi, A. A., M. Amar, R. D. Shamburek, and A. T. Remaley. 2007. Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr. Opin. Investig. Drugs 8: 201-212.
4. Badimon, J. J., L. Badimon, and V. Fuster. 1990. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85: 1234-1241.
5. Sethi, A. A., J. A. Stonik, F. Thomas, S. J. Demosky, M. Amar, E. Neufeld, H. B. Brewer, W. S. Davidson, W. D'Souza, D. Sviridov, and A. T. Remaley. 2008. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J. Biol. Chem. 283: 32273-32282.
6. Tall, A. R., L. Yvan-Charvet, N. Terasaka, T. Pagler, and N. Wang. 2008. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 7: 365-375.
7. Nofer, J. R., A. T. Remaley, R. Feuerborn, I. Wolinnska, T. Engel, A. von Eckardstein, and G. Assmann. 2006. Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter. J. Lipid Res. 47: 794-803.
8. Florentin, M., E. N. Liberopoulos, A. S. Wierzbicki, and D. P. Mikhailidis. 2008. Multiple actions of high-density lipoprotein. Curr. Opin. Cardiol. 23: 370-378.
9. Navab, M., G. M. Anantharamaiah, and A. M. Fogelman. 2005. The role of high-density lipoprotein in inflammation. Trends Cardiovasc. Med. 15: 158-161.
10. Wadham, C., N. Albanese, J. Roberts, L. Wang, C. J. Bagley, J. R. Gamble, K. A. Rye, P. J. Barter, M. A. Vadas, and P. Xia. 2004. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 109: 2116-2122.
11. Baker, P. W., K. A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter. 1999. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J. Lipid Res. 40: 345-353.
12. Sugatani, J., M. Miwa, Y. Komiyama, and S. Ito. 1996. High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J. Lipid Mediat. Cell Signal. 13: 73-88.
13. Xia, P., M. A. Vadas, K. A. Rye, P. J. Barter, and J. R. Gamble. 1999. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem. 274: 33143-33147.
14. Robbesyn, F., N. Augé, C. Vindis, A. V. Cantero, R. Barbaras, A. Negre-Salvayre, and R. Salvayre. 2005. High-density lipoproteins prevent the oxidized low-density lipoprotein-induced epidermal [corrected] growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. Arterioscler. Thromb. Vasc. Biol. 25: 1206-1212.
15. Robbesyn, F., V. Garcia, N. Auge, O. Vieira, M. F. Frisach, R. Salvayre, and A. Negre-Salvayre. 2003. HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cells. FASEB J. 17: 743-745.
16. Brewer, H. B., Jr., A. T. Remaley, E. B. Neufeld, F. Basso, and C. Joyce. 2004. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 24: 1755-1760.
17. Getz, G. S., G. D. Wool, and C. A. Reardon. 2009. Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action. Curr. Opin. Lipidol. 20: 171-175.
18. Segrest, J. P., M. K. Jones, H. De Loof, C. G. Brouillette, Y. V. Venkatachalapathi, and G. M. Anantharamaiah. 1992. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J. Lipid Res. 33: 141-166.
19. Remaley, A. T., F. Thomas, J. A. Stonik, S. J. Demosky, S. E. Bark, E. B. Neufeld, A. V. Bocharov, T. G. Vishnyakova, A. P. Patterson, T. L. Eggerman, et al. 2003. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J. Lipid Res. 44: 828-836.
20. Gomaraschi, M., L. Calabresi, G. Rossoni, S. Iametti, G. Franceschini, J. A. Stonik, and A. T. Remaley. 2008. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. J. Pharmacol. Exp. Ther. 324: 776-783.
21. Anantharamaiah, G. M., V. K. Mishra, D. W. Garber, G. Datta, S. P. Handattu, M. N. Palgunachari, M. Chaddha, M. Navab, S. T. Reddy, J. P. Segrest, and A. M. Fogelman. 2007. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J. Lipid Res. 48: 1915-1923.
22. Johnson, J. R., R. E. Wiley, R. Fattouh, F. K. Swirski, B. U. Gajewska, A. J. Coyle, J. C. Gutierrez-Ramos, R. Ellis, M. D. Inman, and M. Jordana. 2004. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. Am. J. Respir. Crit. Care Med. 169: 378-385.
23. Croy, J. E., T. Brandon, and E. A. Komives. 2004. Two apolipoprotein E mimetic peptides, ApoE(130-149) and ApoE(141-155)2, bind to LRP1. Biochemistry 43: 7328-7335.
24. Lewkowich, I. P., N. S. Herman, K. W. Schleifer, M. P. Dance, B. L. Chen, K. M. Dienger, A. A. Sproles, J. S. Shah, J. Köhl, Y. Belkaid, and M. Wills-Karp. 2005. CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J. Exp. Med. 202: 1549-1561.
25. Lee, C. G., D. Hartl, G. R. Lee, B. Koller, H. Matsuura, C. A. Da Silva, M. H. Sohn, L. Cohn, R. J. Homer, A. A. Kozhich, et al. 2009. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J. Exp. Med. 206: 1149-1166.
26. Nakanishi, A., S. Morita, H. Iwashita, Y. Sagiya, Y. Ashida, H. Shirafuji, Y. Fujisawa, O. Nishimura, and M. Fujino. 2001. Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma. Proc. Natl. Acad. Sci. USA 98: 5175-5180.
27. Chu, H. W., J. L. Halliday, R. J. Martin, D. Y. Leung, S. J. Szefler, and S. E. Wenzel. 1998. Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am. J. Respir. Crit. Care Med. 158: 1936-1944.
28. Barnes, P. J. 2008. The cytokine network in asthma and chronic obstructive pulmonary disease. J. Clin. Invest. 118: 3546-3556.
29. Wills-Karp, M., and F. D. Finkelman. 2008. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci. Signal. 1: pe55.
30. Schnyder-Candrian, S., D. Togbe, I. Couillin, I. Mercier, F. Brombacher, V. Quesniaux, F. Fossiez, B. Ryffel, and B. Schnyder. 2006. Interleukin-17 is a negative regulator of established allergic asthma. J. Exp. Med. 203: 2715-2725.
31. Ying, S., D. S. Robinson, Q. Meng, L. T. Barata, A. R. McEuen, M. G. Buckley, A. F. Walls, P. W. Askenase, and A. B. Kay. 1999. C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J. Immunol. 163: 3976-3984.
32. Walsh, E. R., N. Sahu, J. Kearley, E. Benjamin, B. H. Kang, A. Humbles, and A. August. 2008. Strain-specific requirement for eosinophils in the recruitment of T cells to the lung during the development of allergic asthma. J. Exp. Med. 205: 1285-1292.
33. Pilette, C., J. N. Francis, S. J. Till, and S. R. Durham. 2004. CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge. Eur. Respir. J. 23: 876-884.
34. Loke, P., I. Gallagher, M. G. Nair, X. Zang, F. Brombacher, M. Mohrs, J. P. Allison, and J. E. Allen. 2007. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J. Immunol. 179: 3926-3936.
35. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3: 23-35.
36. Martinez, F. O., L. Helming, and S. Gordon. 2009. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27: 451-483.
37. Kim, S. J., N. Ruiz, K. Bezouska, and K. Drickamer. 1992. Organization of the gene encoding the human macrophage mannose receptor (MRC1). Genomics 14: 721-727.
38. Greenlee, K. J., D. B. Corry, D. A. Engler, R. K. Matsunami, P. Tessier, R. G. Cook, Z. Werb, and F. Kheradmand. 2006. Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J. Immunol. 177: 7312-7321.
39. Iwashita, H., S. Morita, Y. Sagiya, and A. Nakanishi. 2006. Role of eosinophil chemotactic factor by T lymphocytes on airway hyperresponsiveness in a murine model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 35: 103-109.
40. Zimmermann, N., N. E. King, J. Laporte, M. Yang, A. Mishra, S. M. Pope, E. E. Muntel, D. P. Witte, A. A. Pegg, P. S. Foster, et al. 2003. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J. Clin. Invest. 111: 1863-1874.
41. Nair, M. G., Y. Du, J. G. Perrigoue, C. Zaph, J. J. Taylor, M. Goldschmidt, G. P. Swain, G. D. Yancopoulos, D. M. Valenzuela, A. Murphy, et al. 2009. Alternatively activated macrophage-derived RELM-alpha is a negative regulator of type 2 inflammation in the lung. J. Exp. Med. 206: 937-952.
42. National Asthma Education and Prevention Program. 2007. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services.
43. American Thoracic Society. 2000. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am. J. Respir. Crit. Care Med. 162: 2341-2351.
44. Moore, W. C., E. R. Bleecker, D. Curran-Everett, S. C. Erzurum, B. T. Ameredes, L. Bacharier, W. J. Calhoun, M. Castro, K. F. Chung, M. P. Clark, et al; National Heart, Lung, Blood Institute's Severe Asthma Research Program. 2007. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J. Allergy Clin. Immunol. 119: 405-413.
45. Navab, M., S. Y. Hama, G. M. Anantharamaiah, K. Hassan, G. P. Hough, A. D. Watson, S. T. Reddy, A. Sevanian, G. C. Fonarow, and A. M. Fogelman. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 41: 1495-1508.
46. Hyka, N., J. M. Dayer, C. Modoux, T. Kohno, C. K. Edwards, III, P. Roux-Lombard, and D. Burger. 2001. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97: 2381-2389.
47. Kim, K. D., H. Y. Lim, H. G. Lee, D. Y. Yoon, Y. K. Choe, I. Choi, S. G. Paik, Y. S. Kim, Y. Yang, and J. S. Lim. 2005. Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem. Biophys. Res. Commun. 338: 1126-1136.
48. Liao, X. L., B. Lou, J. Ma, and M. P. Wu. 2005. Neutrophils activation can be diminished by apolipoprotein A-I. Life Sci. 77: 325-335.
49. Tang, C., Y. Liu, P. S. Kessler, A. M. Vaughan, and J. F. Oram. 2009. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J. Biol. Chem. 284: 32336-32343.
50. Wilhelm, A. J., M. Zabalawi, J. M. Grayson, A. E. Weant, A. S. Major, J. Owen, M. Bharadwaj, R. Walzem, L. Chan, K. Oka, et al. 2009. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler. Thromb. Vasc. Biol. 29: 843-849.
51. Blackburn, W. D., Jr., J. G. Dohlman, Y. V. Venkatachalapathi, D. J. Pillion, W. J. Koopman, J. P. Segrest, and G. M. Anantharamaiah. 1991. Apolipoprotein A-I decreases neutrophil degranulation and superoxide production. J. Lipid Res. 32: 1911-1918.
52. Bloedon, L. T., R. Dunbar, D. Duffy, P. Pinell-Salles, R. Norris, B. J. DeGroot, R. Movva, M. Navab, A. M. Fogelman, and D. J. Rader. 2008. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 49: 1344-1352.
53. Buga, G. M., J. S. Frank, G. A. Mottino, A. Hakhamian, A. Narasimha, A. D. Watson, B. Yekta, M. Navab, S. T. Reddy, G. M. Anantharamaiah, and A. M. Fogelman. 2008. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet. J. Lipid Res. 49: 192-205.
54. Buga, G. M., J. S. Frank, G. A. Mottino, M. Hendizadeh, A. Hakhamian, J. H. Tillisch, S. T. Reddy, M. Navab, G. M. Anantharamaiah, L. J. Ignarro, and A. M. Fogelman. 2006. D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet. J. Lipid Res. 47: 2148-2160.
55. Van Lenten, B. J., A. C. Wagner, C. L. Jung, P. Ruchala, A. J. Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamaiah, and A. M. Fogelman. 2008. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J. Lipid Res. 49: 2302-2311.
56. Vaziri, N. D., H. Moradi, M. V. Pahl, A. M. Fogelman, and M. Navab. 2009. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int. 76: 437-444.
57. Charles-Schoeman, C., M. L. Banquerigo, S. Hama, M. Navab, G. S. Park, B. J. Van Lenten, A. C. Wagner, A. M. Fogelman, and E. Brahn. 2008. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin. Immunol. 127: 234-244.
58. Van Lenten, B. J., A. C. Wagner, M. Navab, G. M. Anantharamaiah, E. K. Hui, D. P. Nayak, and A. M. Fogelman. 2004. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 110: 3252-3258.
59. Amar, M. J., W. D'Souza, S. Turner, S. Demosky, D. Sviridov, J. Stonik, J. Luchoomun, J. Voogt, M. Hellerstein, D. Sviridov, and A. T. Remaley. 2010. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J. Pharmacol. Exp. Ther. 334: 634-641.
60. Tabet, F., A. T. Remaley, A. I. Segaliny, J. Millet, L. Yan, S. Nakhla, P. J. Barter, K. A. Rye, and G. Lambert. 2010. The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler. Thromb. Vasc. Biol. 30: 246-252.
61. Bortnick, A. E., E. Favari, J. Q. Tao, O. L. Francone, M. Reilly, Y. Zhang, G. H. Rothblat, and S. R. Bates. 2003. Identification and characterization of rodent ABCA1 in isolated type II pneumocytes. Am. J. Physiol. Lung Cell. Mol. Physiol. 285: L869-L878.
62. Bates, S. R., J. Q. Tao, H. L. Collins, O. L. Francone, and G. H. Rothblat. 2005. Pulmonary abnormalities due to ABCA1 deficiency in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 289: L980-L989.
63. Bates, S. R., J. Q. Tao, K. J. Yu, Z. Borok, E. D. Crandall, H. L. Collins, and G. H. Rothblat. 2008. Expression and biological activity of ABCA1 in alveolar epithelial cells. Am. J. Respir. Cell Mol. Biol. 38: 283-292.
64. Lawn, R. M., D. P. Wade, T. L. Couse, and J. N. Wilcox. 2001. Localization of human ATP-binding cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. Arterioscler. Thromb. Vasc. Biol. 21: 378-385.
65. Delvecchio, C. J., P. Bilan, P. Nair, and J. P. Capone. 2008. LXR-induced reverse cholesterol transport in human airway smooth muscle is mediated exclusively by ABCA1. Am. J. Physiol. Lung Cell. Mol. Physiol. 295: L949-L957.
66. Delvecchio, C. J., P. Bilan, K. Radford, J. Stephen, B. L. Trigatti, G. Cox, K. Parameswaran, and J. P. Capone. 2007. Liver X receptor stimulates cholesterol efflux and inhibits expression of proinflammatory mediators in human airway smooth muscle cells. Mol. Endocrinol. 21: 1324-1334.
67. Wurfel, M. M., S. T. Kunitake, H. Lichenstein, J. P. Kane, and S. D. Wright. 1994. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J. Exp. Med. 180: 1025-1035.
68. Lee, S. Y., J. Y. Cho, M. Miller, K. McElwain, S. McElwain, P. Sriramarao, E. Raz, and D. H. Broide. 2006. Immunostimulatory DNA inhibits allergen-induced peribronchial angiogenesis in mice. J. Allergy Clin. Immunol. 117: 597-603.
69. Bates, J., C. Irvin, V. Brusasco, J. Drazen, J. Fredberg, S. Loring, D. Eidelman, M. Ludwig, P. Macklem, J. Martin, et al. 2004. The use and misuse of Penh in animal models of lung disease. Am. J. Respir. Cell Mol. Biol. 31: 373-374.